Extraordinary General Meeting in Modus Therapeutics Holding AB (publ)
29 juli, 11:30
Modus Therapeutics’ Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
- To amend the company’s articles of association in order to increase the limits of the company’s share capital and number of shares, whereby the share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000, and the number of shares shall be not less than 100,000,000 and not more than 400,000,000.
- To approve the Board’s decision of 26 June 2025, regarding issuance of up to 8,984,724 units consisting of shares, warrants of series 2025/2026 and warrants of series 2025/2030 (the “Rights Issue”). The record date for participation in the Rights Issue is 8 August 2025. The right to subscribe for units shall be granted to the Modus Therapeutics’ shareholders, with one (1) existing share entitling the holder to one (1) unit right. The unit right entitles the holder to subscribe for new units with preferential rights. Four (4) unit rights entitle the holder to subscribe for one (1) unit. One (1) unit consists of nine (9) newly issued shares, three (3) warrants of series 2025/2026 and four (4) warrants of series 2025/2030. For further information regarding the Rights Issue, please refer to the previously published press release dated 26 June 2025.
- To authorise the Board to, for the period until the end of the next annual general meeting, on one or more occasions and with deviation from the shareholders’ preferential rights, resolve on new issue of shares and/or warrants. The right to subscribe for shares and/or warrants shall be primarily granted to those who have entered into guarantee undertakings to guarantee the Rights Issue announced by the Company on 26 June 2025, but also other potential investors who are not shareholders in the Company and who wish to invest in the Company in connection with the Rights Issue.
For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se
About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.
Attachments
Extraordinary General Meeting in Modus Therapeutics Holding AB (publ)
Ämnen i artikeln
Extraordinary General Meeting in Modus Therapeutics Holding AB (publ)
29 juli, 11:30
Modus Therapeutics’ Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
- To amend the company’s articles of association in order to increase the limits of the company’s share capital and number of shares, whereby the share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000, and the number of shares shall be not less than 100,000,000 and not more than 400,000,000.
- To approve the Board’s decision of 26 June 2025, regarding issuance of up to 8,984,724 units consisting of shares, warrants of series 2025/2026 and warrants of series 2025/2030 (the “Rights Issue”). The record date for participation in the Rights Issue is 8 August 2025. The right to subscribe for units shall be granted to the Modus Therapeutics’ shareholders, with one (1) existing share entitling the holder to one (1) unit right. The unit right entitles the holder to subscribe for new units with preferential rights. Four (4) unit rights entitle the holder to subscribe for one (1) unit. One (1) unit consists of nine (9) newly issued shares, three (3) warrants of series 2025/2026 and four (4) warrants of series 2025/2030. For further information regarding the Rights Issue, please refer to the previously published press release dated 26 June 2025.
- To authorise the Board to, for the period until the end of the next annual general meeting, on one or more occasions and with deviation from the shareholders’ preferential rights, resolve on new issue of shares and/or warrants. The right to subscribe for shares and/or warrants shall be primarily granted to those who have entered into guarantee undertakings to guarantee the Rights Issue announced by the Company on 26 June 2025, but also other potential investors who are not shareholders in the Company and who wish to invest in the Company in connection with the Rights Issue.
For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se
About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.
Attachments
Extraordinary General Meeting in Modus Therapeutics Holding AB (publ)
Ämnen i artikeln
Handelskrig
Apple
Analys
Handelskrig
Mest läst
Apple
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
